Proof-of-Concept Randomized Controlled Study of Cognition Effects of the Proprietary Extract Sceletium tortuosum (Zembrin) Targeting Phosphodiesterase-4 in Cognitively Healthy Subjects: Implications for Alzheimer's Dementia.
Quick navigation
Link to full study
http://www.ncbi.nlm.nih.gov/pubmed/25389443
Conclusion of this study
The promising cognitive enhancing effects of Zembrin likely implicate the PDE-4-cAMP-CREB cascade, a novel drug target in the potential treatment of early Alzheimer's dementia. This trial is registered with ClinicalTrials.gov NCT01805518.
Supplements analyzed in this study
Health conditions analyzed in this study
No health conditions information for this study.
Functions related to this study
Body systems related to this study